title: Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study.
abstract: OBJECTIVE
  To investigate the association between dopaminergic polymorphisms [DRD2 -141C Ins/Del, DRD3 Ser9Gly, and SLC6A3 VNTR] and schizophrenia.
  
  
  METHODS
  Two hundred and eighty-eight outpatients with schizophrenia (DSM-IV criteria) [mean age (SD)=36.4 (12.4), 60.1% males] and 421 unrelated healthy controls [mean age (SD)=40.6 (11.3), 51.3% males] from a homogeneous Spanish Caucasian population were genotyped using standard methods.
  
  
  RESULTS
  There was a significant difference in genotype distribution for the DRD2 -141C Ins/Del polymorphism [(chi(2) (2)=12.35, corrected p=0.012]. The -141C Del allele was more common in patients than in controls [0.19 vs. 0.13; chi(2) (1)=9.14, corrected p=0.018, OR (95% CI)=1.57 (1.17-2.10)]. Genotype and allele distributions for DRD3 Ser9Gly and SLC6A3 VNTR polymorphisms were similar in both groups. However, there was tentative evidence of an interaction effect between DRD3 Ser9Gly and SLC6A3 VNTR [Wald=9.56 (4), p=0.049]. Compared to the SLC6A3 10/10 genotype category, the risk of schizophrenia was halved among those with 9/10 [OR=0.51 (95% CI=0.30-0.89), p=0.017]. This protective effect was only present in combination with DRD3 Ser/Ser genotype because of the significant interaction between 9/10 and both Ser/Gly [OR=2.45 (95% CI=1.16-5.17), p=0.019] and Gly/Gly [OR=3.80 (95% CI=1.24-11.63), p=0.019].
  
  
  CONCLUSIONS
  This study provides evidence that a genetic variant in the DRD2 gene and possible interaction between DRD3 and SLC6A3 genes are associated with schizophrenia. These findings warrant examination in replication studies.
authors.affiliation: Department of Psychiatry, School of Medicine, University of Oviedo, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Julian Claveria 6, 33006, Oviedo, Spain. frank@uniovi.es
authors.forename: Pilar A
authors.initials: PA
authors.lastname: Sáiz
authors.forename: M Paz
authors.initials: MP
authors.lastname: García-Portilla
authors.forename: Celso
authors.initials: C
authors.lastname: Arango
authors.forename: Blanca
authors.initials: B
authors.lastname: Morales
authors.forename: Bárbara
authors.initials: B
authors.lastname: Arias
authors.forename: Paul
authors.initials: P
authors.lastname: Corcoran
authors.forename: Juan M
authors.initials: JM
authors.lastname: Fernández
authors.forename: Victoria
authors.initials: V
authors.lastname: Alvarez
authors.forename: Eliecer
authors.initials: E
authors.lastname: Coto
authors.forename: María-Teresa
authors.initials: MT
authors.lastname: Bascarán
authors.forename: Manuel
authors.initials: M
authors.lastname: Bousoño
authors.forename: Lourdes
authors.initials: L
authors.lastname: Fañanas
authors.forename: Julio
authors.initials: J
authors.lastname: Bobes
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D055106:Genome-Wide Association Study / Q000379:methods; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D018598:Minisatellite Repeats / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D050637:Receptors, Dopamine D3 / Q000235:genetics*; D012559:Schizophrenia / Q000235:genetics*; D013030:Spain; D055815:Young Adult
chemical_list: C493593:DRD3 protein, human; D050483:Dopamine Plasma Membrane Transport Proteins; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C493214:SLC6A3 protein, human